In the context of proteasome inhibitors (PIs) and immunomodulatory drugs as the cornerstone of treatment, the CD38 monoclonal antibodies daratumumab and isatuximab continue to play a leading role at the forefront of multiple myeloma therapy. This evidence concerns the gene CD38 and plasma cell myeloma.